Novo Nordisk claims Wegovy shows greater weight loss than Eli Lilly's rival pill

A cross-trial comparison shows Novo's oral semaglutide produced three percentage points more weight loss and fewer dropouts due to side effects

Michael Siluk / UCG / Universal Images Group via Getty Images

Novo Nordisk published a cross-trial comparison claiming its Wegovy pill produced greater weight loss than Eli Lilly $LLY's newly approved obesity tablet Foundayo, raising the stakes as the two companies compete to shape prescribing trends in the oral GLP-1 market.

The comparison found that Novo's 25 mg dose of oral semaglutide caused 3.2 percentage points more weight loss than Lilly's 36 mg orforglipron — regardless of whether patients stayed on treatment. The study also found that patients on orforglipron, under the brand name Foundayo, had roughly 14 times the odds of stopping treatment due to........

© Quartz